zealand pharma glp 1 Petrelintide - Pipeline Zealand Pharma wants a big

It is about protecting your results

[DOI] [PubMed] [Google Scholar] [203].Holst JJ, Madsbad S, Semaglutide seems to be more effective the other GLP-1Ras, Ann Transl Med, 5 (2017) 505

PMID 20733935

lab acknowledges funding from BBSRC (BB/V019791/1) and MRC (MR/W024985/1)

I feel much calmer

In 2025, Novo Nordisks semaglutide awaits several first-time FDA decisions: 3Q 2025 the first GLP-1 (Wegovy) for metabolic dysfunction-associated steatohepatitis (MASH) 4Q 2025 the first oral GLP-1 ( oral formulation of Wegovy 25 mg ) for weight loss and weight loss plus secondary CV risk reduction 4Q 2025 Wegovy for heart failure with preserved ejection fraction and obesity October 2025 new indication for oral Rybelsus for secondary CV risk reduction 2025 Ozempic for T2DM and peripheral artery disease (PAD) Given the considerable continued growth expected in the GLP-1 pipeline, Prime Therapeutics (Prime) talented team of clinical experts actively monitors this emerging landscape